TSX Exchange Symbol: RVX
CALGARY, Feb. 6, 2014 /CNW/ - Resverlogix Corp. (TSX:RVX) will be
hosting a conference call and webcast on Thursday, February 13, 2014 at
11 am MDT / 1 pm ET. The call will update the market on current
clinical and business structure options.
Details for the conference call and webcast are as follows:
Link to webcast: http://services.choruscall.ca/links/resverlogix140213.html
Dial in numbers:
Canada & USA Toll Free Dial In: 1-800-319-4610
Outside of Canada & USA call: +1-604-638-5340
About Resverlogix
Resverlogix Corp. (TSX:RVX) is a clinical stage biotechnology company
developing compounds involving ApoA-I production. RVX-208 is a
first-in-class small molecule in development for the treatment of
diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer's
disease. RVX-208 is the first BET bromodomain inhibitor in clinical
trials. Resverlogix's common shares trade on the Toronto Stock Exchange
(TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog and our IR App found on Apple products iTunes and Android users (Google Play).
|
Company Contacts:
|
|
|
|
|
| |
|
|
|
|
Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: 403-254-9252
Email: don@resverlogix.com
|
|
|
|
Kenneth Lebioda
SVP Business & Corporate Development
Resverlogix Corp.
Phone: 403-254-9252
Email: ken@resverlogix.com
|
SOURCE Resverlogix Corp.
Copyright CNW Group 2014